[I]MIBG is a better early marker of anthracycline cardiotoxicity than [F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study.

Fiche publication

Date publication

septembre 2021

Journal

EJNMMI research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRUNOTTE François , Dr COLLIN Bertrand , Pr COCHET Alexandre

Tous les auteurs :
Oudot A, Courteau A, Guillemin M, Vrigneaud JM, Walker PM, Brunotte F, Cochet A, Collin B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34542689

Résumé

During anthracycline treatment of cancer, there is a lack for biomarkers of cardiotoxicity besides the cardiac dysfunction. The objective of the present study was to compare [F]FDG and [I]MIBG (metaiodobenzylguanidine) in a longitudinal study in a doxorubicin-induced cardiotoxicity rat model.